ArticleBMC microbiology2026
Antimicrobial and antibiofilm activity of a novel bacteriophage endolysin (LysSW21) against methicillin-resistant Staphylococcus aureus.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rise of antibiotic-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), poses a critical global health challenge. Endolysins, which enzymatically degrade bacterial cell walls, represent a promising class of antimicrobial agents. This study aimed to express and characterize the endolysin LysSW21, derived from the previously characterized Staphylococcus phage vB_SauR_SW21, and evaluate its antibacterial and antibiofilm activities against MRSA strains.
resultsIn silico analysis of LysSW21 revealed a modular structure comprising an N-terminal CHAP catalytic domain (residues 20–107) and a C-terminal SH3b cell wall-binding domain (residues 164–228). The recombinant protein was successfully expressed in Escherichia coli BL21 (DE3) and purified. LysSW21 demonstrated potent bactericidal activity against reference MRSA strains (MIC/MBC: 25 μg/mL) and a clinical isolate from diabetic foot ulcer (MIC/MBC: 12.5 μg/mL). Time-kill assays revealed rapid, concentration-dependent killing, with complete eradication of planktonic MRSA within 75 min at 2 × MIC (50 μg/mL) and within 105 min at MIC (25 μg/mL). The enzyme exhibited remarkable stability across a broad temperature range (4–70°C) and pH range (4.5–10.5), maintaining 4–5 log₁₀ reductions in bacterial viability. Importantly, crystal violet assay and field emission scanning electron microscopy confirmed concentration-dependent antibiofilm activity of LysSW21, with 70–80% biofilm disruption at 4 × MIC against MRSA strains.
conclusionsLysSW21 exhibits potent bactericidal activity against planktonic MRSA and effectively disrupts biofilms with high stability under diverse environmental conditions. These properties position LysSW21 as a promising candidate for further preclinical development against biofilm-associated MRSA infections. Future studies should evaluate its efficacy and safety in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.